P1.21-11 Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50%

J. Suga,S. Thomas,N. Achacoso,C. Jiang, E. Chung, A. Solorzano-Pinto, P. Tse, B.J. Bulen, N.A. Khazanov, L.E. Lamb,D.H. Hovelson, K. Kwiatkowski,D.B. Johnson,D.R. Rhodes,S.A. Tomlins,L.A. Habel

Journal of Thoracic Oncology（2023）

Cited 0|Views20

No score

Abstract

Immunotherapy Response Score (IRS) is a tissue-based multivariable algorithm previously validated to predict anti-PD-(L)1 benefit pan-tumor (PMID:36750617) from routine tissue samples. We evaluated IRS in an independent cohort of Kaiser Permanente Northern California (KPNC) patients with advanced non-small cell lung cancer (NSCLC) following a pre-specified statistical analysis plan for the primary objective.

Translated text

Key words

pembrolizumab clinical benefit,immunotherapy response score,immunotherapy response

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined